The Impact of the Menstrual Cycle and Underlying Hormones in Anxiety and PTSD: What Do We Know and Where Do We Go From Here?

被引:28
|
作者
Nillni, Yael, I [1 ,2 ]
Rasmusson, Ann M. [1 ,2 ]
Paul, Emilie L. [3 ]
Pineles, Suzanne L. [1 ,2 ]
机构
[1] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA
[2] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA
[3] Boston Med Ctr, Dept Psychiat, Boston, MA USA
关键词
Anxiety disorder; Post-traumatic stress disorder; Menstrual cycle; Extinction recall; CO2; challenge; Premenstrual exacerbation; POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN 2A RECEPTOR; SEX-DIFFERENCES; PSYCHIATRIC-DISORDERS; PREMENSTRUAL-SYNDROME; REPRODUCTIVE-CYCLE; GENDER-DIFFERENCES; ESTROGEN-LEVELS; WOMEN; FEAR;
D O I
10.1007/s11920-020-01221-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Purpose of ReviewThis paper reviews the recent literature on menstrual cycle phase effects on outcomes relevant to anxiety and PTSD, discusses potential neurobiological mechanisms underlying these effects, and highlights methodological limitations impeding scientific advancement.Recent FindingsThe menstrual cycle and its underlying hormones impact symptom expression among women with anxiety and PTSD, as well as psychophysiological and biological processes relevant to anxiety and PTSD.SummaryThe most consistent findings are retrospective self-report of premenstrual exacerbation of anxiety symptoms and the protective effect of estradiol on recall of extinction learning among healthy women. Lack of rigorous methodology for assessing menstrual cycle phase and inconsistent menstrual cycle phase definitions likely contribute to other conflicting results. Further investigations that address these limitations and integrate complex interactions between menstrual cycle phase-related hormones, genetics, and psychological vulnerabilities are needed to inform personalized prevention and intervention efforts for women.
引用
收藏
页数:9
相关论文
共 50 条
  • [42] cAMP-PKA signaling pathway and anxiety: Where do we go next?
    Chen, Daokang
    Wang, Jingji
    Cao, Jian
    Zhu, Guoqi
    CELLULAR SIGNALLING, 2024, 122
  • [43] What Can We/Do We Want to Know? Reflections from Researching SGBV in Military Settings
    Baaz, Maria Eriksson
    Gray, Harriet
    Stern, Maria
    SOCIAL POLITICS, 2018, 25 (04): : 521 - 544
  • [44] Contralateral Prophylactic Mastectomy: What Do We Know and What Do Our Patients Know?
    Khan, Seema A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2132 - 2135
  • [45] The Social and Economic Impact of Covid-19 on Family Functioning and Well-Being: Where do we go from here?
    Andrade, Claudia
    Gillen, Martie
    Molina, Jose Alberto
    Wilmarth, Melissa J.
    JOURNAL OF FAMILY AND ECONOMIC ISSUES, 2022, 43 (02) : 205 - 212
  • [46] Antidepressants' effects on testosterone and estrogens: What do we know?
    Pavlidi, Pavlina
    Kokras, Nikolaos
    Dalla, Christina
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 899
  • [47] Zika virus infection and pregnancy: what we do and do not know
    Ticconi, Carlo
    Pietropolli, Adalgisa
    Rezza, Giovanni
    PATHOGENS AND GLOBAL HEALTH, 2016, 110 (7-8) : 262 - 268
  • [48] Cancer screening in the aging population: Where do we stand and what can we do?
    Cao, Wei
    Chen, Wanqing
    JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03): : 127 - 129
  • [49] Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know
    Chang, Tien-Lin
    Kuo, Hann-Chorng
    TZU CHI MEDICAL JOURNAL, 2024, 36 (04): : 370 - 376
  • [50] PCOS and Hyperprolactinemia: what do we know in 2019?
    Delcour, Clemence
    Robin, Geoffroy
    Young, Jacques
    Dewailly, Didier
    CLINICAL MEDICINE INSIGHTS-REPRODUCTIVE HEALTH, 2019, 13